The Orthocell Ltd (ASX: OCC) share price is rising today following news of a successful pilot animal study. The company states that as a result of the study, it’s seeking to fast-track US approval for its CelGro product.
The Orthocell share price is currently trading at 54 cents, up 4.85% from yesterday’s closing price.
Let’s take a closer look at the latest news released by the regenerative medicine company.
Positive study results
Orthocell released the news today that the results of its pilot animal study indicate that CelGro facilitates nerve regeneration in a superior manner compared to current market-leading nerve repair devices. It was found to effectively regenerate nerves. In particular, it is able to restore an…
Business23 hours ago
Victoria Covid exposure sites: full list of Melbourne and regional Vic coronavirus hotspots and trend in cases – The Guardian Australia
Sport21 hours ago
Protest dismissed: State Of Rest’s Cox Plate triumph – The Age
Technology18 hours ago
Will miHoYo Ever Take the Issue of Horrible Endgame of Genshin Impact Seriously? – EssentiallySports
Technology15 hours ago
Google Meet Hosts Can Now Mute People for As Long As They Want – PCMag AU